Pheochromocytomas, MEN 2A and Pregnancy: A Case Report with Review of the Literature

Benzon M Dy, Eitan Podgaetz, William F Young, Geoffrey B Thompson

ABSTRACT
Pheochromocytoma in pregnancy is a rare condition with an estimated incidence of one in 54,000 pregnancies. Pheochromocytoma in the setting of multiple endocrine neoplasia (MEN) type 2A develops in approximately 40% of the patients with this germline mutation. MEN 2A patients with pheochromocytoma are often asymptomatic compared to those with nonsyndromic pheochromocytoma. We present a 28-year-old pregnant woman with a known MEN 2A mutation who was incidentally found to have a pheochromocytoma. She underwent an uncomplicated laparoscopic right adrenalectomy after proper \( \alpha \)- and \( \beta \)-adrenergic blockade. Her serum fractionated metanephrines normalized prior to discharge from the hospital. The remainder of her pregnancy was uneventful and she delivered a healthy baby at term. Pheochromocytoma in pregnancy requires careful management to assure the well-being of both the mother and the fetus. In pregnancy, laparoscopic surgical removal of the pheochromocytoma is feasible with excellent results when performed in the second trimester. In late pregnancy, medical management with close monitoring of the mother and fetus is recommended until fetal maturity is achieved. In the third trimester, cesarean section and open adrenalectomy is the preferred operation. In the third trimester, cesarean section followed by open adrenalectomy is the preferred operation. An integrated and multidisciplinary approach with close communication among the endocrinologist, surgeon and perinatal services is paramount to achieve excellent outcomes for both patients. Women with MEN 2 should be advised to refrain from pregnancy until updated biochemical and imaging studies have ruled out pheochromocytoma.

Keywords: MEN 2A, Pheochromocytoma, Pregnancy.


Source of support: Nil

Conflict of interest: None

INTRODUCTION
A 28-year-old asymptomatic woman was referred by her local primary care physician for definitive management of her pheochromocytoma at 10 weeks gestation. Physical examination revealed a blood pressure of 100/71 mm Hg, pulse of 77 beats per minute, normal heart and lung findings.

She had been diagnosed with a RET proto-oncogene mutation at age 14 and underwent a total thyroidectomy with no evidence of medullary thyroid cancer. She had annual biochemical testing for pheochromocytoma, testing positive for the first time in 2006 at age 26 and a 2 cm left adrenal mass was identified on imaging. She underwent laparoscopic left adrenalectomy at an outside hospital without complications. Her CT scan at that time did not reveal an abnormality in the right adrenal gland (Fig. 1).

After her left adrenalectomy, she had been attempting to become pregnant and had miscarriages in September of 2007 and January of 2008.

A follow-up CT scan of her abdomen in February of 2008 revealed a 2.8 × 1.9 right adrenal mass (Fig. 2). Her laboratory values are mentioned in Table 1.

The \( \beta \)-hCG screening test was positive, confirmed with a quantitative \( \beta \)-hCG and a fetal ultrasound.

She had been relatively asymptomatic with systolic pressures of 100 to 110 mm Hg since her left adrenalectomy 2 years previously. However, over those 2 years she had experienced occasional palpitations and a sense of a ‘rush’ when she laid down.

The patient was started on an \( \alpha \)-1 adrenergic receptor antagonist, doxazosin 1 mg by mouth daily at bedtime, and she continued to monitor her blood pressure twice daily. Two weeks prior to her planned right adrenalectomy, doxazosin was discontinued and phenoxybenzamine was initiated at 10 mg daily. Five days before her procedure, she was started on propranolol 10 mg four times daily for the first 2 days and then switched to long-acting propranolol 60 mg daily. The phenoxybenzamine dosage was increased to 20 mg per day 3 days prior to her surgery.

Fig. 1: Normal right adrenal gland in 2005 during evaluation for her left adrenal pheochromocytoma
She also met with our perinatal specialists before her surgery who recommended pre- and postprocedure fetal heart rate assessments, epidural analgesia and serial ultrasound every 3 to 4 weeks until completion of her pregnancy. Because of her previous adrenalectomy, resection of her pheochromocytoma with an adrenalectomy would require permanent glucocorticoid and mineralocorticoid replacement therapy.

The morning of her procedure, she received methylprednisolone sodium succinate 20 mg intravenously and another 20 mg that same evening. She then underwent an uneventful laparoscopic right adrenalectomy. There where no intraoperative blood pressure abnormalities during the operation. Blood loss was minimal. Pathology revealed a 3.0 × 3.0 × 2.8 cm pheochromocytoma. Her glucocorticoid dosages were tapered to a dismissal dosage of hydrocortisone 10 mg twice daily and fludrocortisone 0.1 mg daily.

Fetal heart sounds pre- and postoperatively were monitored and normal (Fig. 3).

She recovered well and was discharged home 2 days later in good condition. Ten days after her procedure, she was feeling well and her plasma metanephrines and normetanephrines normalized.

The patient was advised to continue annual fractionated metanephrine, calcitonin and serum calcium testing.

**PHEOCHROMOCYTOMA, PREGNANCY AND MEN 2A**

Pheochromocytoma during pregnancy is a rare phenomenon occurring in fewer than 0.002% of all pregnancies.¹

Pheochromocytomas arise from the chromaffin and sustentacular cells of the adrenal medulla and in extra-adrenal paraganglia.

As many as one fourth of pheochromocytomas can be associated with the RET proto-oncogene mutations (MEN 2A and 2B), the VHL tumor suppressor gene mutations (Von Hippel-Lindau disease) and with NF1 tumor suppressor gene mutations (neurofibromatosis type 1). With modern molecular analysis, the familial incidence of pheochromocytoma and paraganglioma has proven to be approximately 25%.² ³

MEN 2 is an autosomal dominant disorder with an estimated prevalence of 2.5 per 100,000. MEN 2A has a hereditary predisposition to medullary thyroid carcinoma (90%), pheochromocytoma (40-50%) and primary parathyroid hyperplasia (10-20%). Pheochromocytomas in MEN 2A patients are bilateral in 40% of patients as opposed to sporadic disease, which is most often unilateral.⁴ Germline mutation testing is the best screening test for this disorder.

Classically, pheochromocytomas secrete epinephrine, norepinephrine or dopamine, but a milieu of other hormones have been isolated from these tumors. Patients may either be asymptomatic or present with several hallmarks of pheochromocytomas, such as hypertensive spells with headaches, sweating, palpitations, paroxysmal hypertension or feelings of impending ‘doom’.

Pheochromocytoma in pregnancy carries a maternal mortality rate of approximately 40% and a fetal death rate exceeding 50%.⁵

<table>
<thead>
<tr>
<th>Table 1: Laboratory values</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Measurement</strong></td>
</tr>
<tr>
<td>Urine metanephrine</td>
</tr>
<tr>
<td>Urine normetanephrine</td>
</tr>
<tr>
<td>Urine norepinephrine</td>
</tr>
<tr>
<td>Urine epinephrine</td>
</tr>
<tr>
<td>Plasma metanephrine</td>
</tr>
<tr>
<td>Plasma normetanephrine</td>
</tr>
</tbody>
</table>

Fig. 2: CT scan in 2008: Right adrenal mass measuring 2.8 x 1.9 cm

Fig. 3: Normal postoperative US with fetal heart rate monitoring
In sporadic pheochromocytoma, symptoms can be misdiagnosed as preeclampsia, which is by far the most common cause of hypertension during pregnancy. Pre-eclampsia is characterized by hypertension, proteinuria, peripheral edema, headache and hyperreflexia; symptoms that may be difficult to differentiate from a pheochromocytoma. Preeclampsia resolves with delivery whereas symptoms related to pheochromocytoma do not and may even be exacerbated during delivery.

**DIAGNOSIS**

Collection of a 24-hour urine for measurement of fractionated metanephrines and catecholamines is an excellent case detection test for pheochromocytoma. Plasma levels and fractionated metanephrines have a high sensitivity for detecting pheochromocytoma but have a higher false positive rate than urinary studies. Plasma levels are used more frequently in children or in familial cases with a high index of suspicion.

MRI is the imaging method of choice in a pregnant patient because it lacks ionizing radiation. Pheochromocytomas on MRI display a high signal intensity on T2-weighted images and have high water density on chemical shift MRI, offering both anatomical and physiologic evidence of a pheochromocytoma. Our patient had a CT scan performed before her pregnancy. In non-pregnant patients, CT is the best and most cost-effective imaging modality with an overall accuracy greater than 90%. Also in nonpregnant patients, nuclear medicine studies, such as 123I-metaiodobenzylguanidine (MIBG) scintigraphy has reported sensitivities of 80 to 90% as the agent concentrates in adrenergic vesicles.

It is of critical importance to provide adequate alpha-adrenergic blockade followed beta-adrenergic blockade when possible in the same fashion as nonpregnant patients. Phenoxybenzamine is safe and well tolerated during pregnancy. The desired end point of alpha-adrenergic blockade is low normal blood pressure for age. Patients are encouraged to consume a high sodium diet and to increase their fluid intake to expand their intravascular volume with hopes of minimizing blood pressure swings intraoperatively and prevent hypotension postoperatively. We usually add a beta-adrenergic blockade 2 to 3 days prior to surgery and titrate for a target heart rate of 80 beats per minute. There is concern with the use of beta-adrenergic blockade during pregnancy because of the potential for intrauterine growth retardation, but the advantages far outweigh these risks.

Pheochromocytoma is a life-threatening tumor and should be treated aggressively. We recommend operating during the second trimester of pregnancy as the benefits of a controlled and planned operation outweigh the risks of term delivery with a concurrent pheochromocytoma. Our operation of choice is a laparoscopic adrenalectomy. Other options include cortical sparing adrenalectomy which may obviate the need for long-term corticosteroid replacement therapy. However, there is a known increase of recurrent pheochromocytoma when the cortex is spared and up to two-thirds of patients ultimately require ongoing corticosteroid replacement.

If the fetus is greater than 24 weeks gestation, medical management can be attempted with very close maternal and fetal monitoring. Once the fetus is mature, cesarean section should be performed followed by tumor excision.

**CONCLUSION**

Pheochromocytomas are rare in pregnancy. Female patients with known familial predisposition for pheochromocytomas should have yearly case detection testing. If pregnancy is desired the recommendation is to do additional case detection testing prior to the pregnancy, including adrenal-directed imaging with CT or MRI.

In cases in which a pheochromocytoma is detected during pregnancy, early intervention via a planned laparoscopic procedure with adequate preoperative medical preparation can be achieved with high success rates. If the pheochromocytoma is discovered after the 24th week of gestation, it is not unreasonable to medically manage the patient until the fetus is viable at which point both a cesarean section and the removal of the tumor can be performed during the same operative time.

An integrated multidisciplinary approach with close communication between endocrinologist, surgeons and perinatal services is paramount to achieve excellent outcomes for both patients.

**REFERENCES**


ABOUT THE AUTHORS

**Benzon M Dy**
Resident, Department of General Surgery, Mayo Clinic, Minnesota United States

**Eitan Podgaetz**
Resident, Department of General Surgery, Mayo Clinic, Minnesota United States

**William F Young**
Professor, Department of Endocrinology, Mayo Clinic, Minnesota United States

**Geoffrey B Thompson (Corresponding Author)**
Section Head, Department of Endocrine Surgery, Mayo Clinic 200 1st Street SW, Rochester, Minnesota-55905, United States e-mail: thompson.geoffrey@mayo.edu